Are you taking a piss?
AN ARTICLE by Bobby Rapscallion
Alot of times we’re asked about drug tests or a urinalysis and how it works in relation to CBD. Meaning, some people have this concept that CBD and THC are the same. Especially when it comes to drug tests.
CBD does not equal THC
Some people that are new to CBD often have their first experience with a full-spectrum/THC product, or one that has a Delta-8 (D8), Delta-9 (D9), or even a kratom factor. Even worse a 1 for 1 (or 1&1) product that has really heavy potency percentages.
So some, after that experience, are often petrified by the overwhelming experience they had, and because now they have this unknown factor of their urine being tested.
No judgement here. How things happened is not for us to point out. All we’re wanting to do is help inform on the options, issues and what to consider for future use.
So, let’s get to it.
What is in a spectrum?
There are many ways to experience CBD, so we’ll just keep it simple with what we do as a brand – oils, gummies, and topicals (in the future). We’ll also not complicate things with the methods or combos the CBD is manufactured, and just stick to the categories or spectrums – BROAD and FULL.
Broad-spectrum products go through an extra process in production that removes all traces of THC. They are still rich in terpenes and cannabinoids, but you don’t have THC to worry about.
Whereas full-spectrum CBD products can only contain up to 0.3% THC (0.2% internationally), which isn’t enough to produce any intoxicating effects (even at high doses). However, if you undergo drug testing, the trace amounts of THC may result in a build-up of metabolites in your system that may trigger a positive result.
This means…yeah, it can likely show up in a test.
What shows in a test
So a urinalysis, specifically for the one used in a drug test, will look for certain components found in drugs, and one, in particular, is THC.
CBD will not show up in a drug test (unless specifically analyzed), but THC will show up if you have taken a full-spectrum product. This is especially if you’ve taken a CBD product with far more unregulated synthetics like D8 and/or D9.
Even if you’re in a city or state that is ok with a synthetic (some are ok with D8 but not D9), they still show up as THC. There isn’t any general drug test that will isolate the source of the THC coming from wee, D8, D9, etc. You’ll just get popped for having THC in your system.
Not the case for CBD.
With broad-spectrum there is 0% THC in it, thus nothing to show for it. There are plenty of fine product options that comes in broad-spectrum. Regardless if it is one of our products or not, we can honestly say that this is one of best options for someone that subject to drug test (whether it is scheduled or random).
So nothing to worry about in regards to being tested; within the aspect of CBD.
To sum it all up
We recommend that if you are a person that is subject to drug tests, the best option for you is broad-spectrum products that have 0%THC (or any other synthetic THC product).
We feel that this is the best option, to experience and/or apply CBD to your lifestyle, while also receiving the benefits of it.
This is one of the primarily reasons why we decided to have our line start with broad-spectrum products. We wanted people that have this restriction to be able to have the benefit of CBD without the worry of THC in their system. That is unneeded stress and we’re all about NO STRESS.
Bobby Rapscallion’s CBD Products
At Bobby Rapscallion, honesty and integrity are values put into everything. Our hemp is farmed on American soil using organic practices. Our extracts are meticulously tested by our team and a third-party lab to ensure the highest quality standards. Since we stand firmly behind the profound effects of the entourage effect, you won’t find CBD isolate products in our catalog—but we understand that full-spectrum products aren’t ideal for everyone, which is why most of our products are also available in a THC-free broad-spectrum option.
Our high-potency oils start at a Potency Level 1 for those that are wanting to ease into CBD but need a higher dose. Keeping to this focus, we’ll be releasing Potency Levels 2 & 3 in the future. This is to make sure that all of our customers have the option to get high-quality CBD at a potency level that works best for them.
Our CBD Oil
CBD oils are a product staple for a CBD brand. We’ve carefully crafted our CBD oils to keep our high-quality hemp crops the star of the show. CBD oil also provides a wide range of versatility as you can take them sublingual (under the tongue) for fast-acting effects, or mix our flavored options into your favorite foods and drinks for wellness with a unique twist. CBD oils are a favorite for beginners and experts alike for their versatility and because you can customize your doses drop by drop.
our CBD Gummies
For those who don’t enjoy the natural bitter terpene flavor in hemp oils, but still want the whole plant benefits, CBD gummies might be a better solution for you.
We create selectively-crafted gummies at a cGMP facility and make them fresh to order. These also come in assorted flavors to mask the hempy taste and potencies start at 45MG per gummy.
Always remember that the ingestion process is different between oils and edibles like gummies. So we provide products that allow you to decide what works best for you and how you want to experience CBD.
Resources:
- Haj-Dahmane, S., & Shen, R. Y. (2011). Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology, 61(3), 414–420.
- Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry, 2(3), e94.
- Peer W. F. Karmaus, James G. Wagner, Jack R. Harkema, Norbert E. Kaminski, Barbara L. F. Kaplan. (2013). Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. Journal of Immunotoxicology 10:3, pages 321-328.
- Blake, A., Wan, B. A., Malek, L., DeAngelis, C., Diaz, P., Lao, N., & O’Hearn, S. (2017). A selective review of medical cannabis in cancer pain management. Ann Palliat Med, 6(Suppl 2), S215-S222
Related Posts
